Arterial occlusive disease is the leading cause of death in Western countries. Core
contemporary therapies for this disease include angioplasties, stents, endarterectomies and …

Over the past 40 years, the safety and efficacy of percutaneous coronary intervention has
dramatically improved by overcoming several challenges. The introduction of drug-eluting …

Background In patients with coronary in-stent restenosis (ISR) requiring reintervention, it is
unclear if the choice of treatment should depend on whether the restenotic stent was a bare …

To reduce incidences of in‐stent restenosis and thrombosis, the use of a thinner‐strut stent
has been clinically proven to be effective. Therefore, the contemporary trend is toward the …

Aims Contemporary 2nd-generation thin-strut drug-eluting stents (DES) are considered
standard of care for revascularization of patients undergoing percutaneous coronary …

Background Outcome data after extended long-term follow-up of patients with coronary
artery disease treated with drug-eluting stents (DES) in randomized clinical trials are scant …

Background Biodegradable polymer sirolimus-eluting stents improve early stent-related
clinical outcomes compared to durable polymer everolimus-eluting stents in patients with ST …

Cardiovascular disease is the greatest cause of death worldwide. Atherosclerosis is the
underlying pathology responsible for two thirds of these deaths. It is the age‐dependent …

Objectives The aim of this study was to compare late-term clinical outcomes among patients
treated with ultrathin-strut (60-μm) bioresorbable-polymer sirolimus-eluting stents (BP SES) …

Objectives The aim of this study was to investigate the safety and efficacy of biodegradable-
polymer sirolimus-eluting stents (BP-SES) compared with durable-polymer everolimus …